About: An open label cluster randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID‐19 (ARCHAIC)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: An open label cluster randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID‐19 (ARCHAIC) – Protocol publication Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	An open label cluster randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID‐19 (ARCHAIC) – Protocol publication
Source	Medline; PMC
abstract	Chloroquine (CQ) and hydroxychloroquine (HCQ) were both employed in the treatment of COVID‐19 in China. Based on unpublished anecdotal positive results in China, CQ is now implemented in China and the Netherlands in moderate to severe COVID‐19.
has issue date	2020-05-31(xsd:dateTime)
bibo:doi	10.1111/eci.13297
bibo:pmid	32474918
has license	no-cc
sha1sum (hex)	71403b97afb2fced959e2d5a1b146ede82872dcd
schema:url	https://doi.org/10.1111/eci.13297
resource representing a document's title	An open label cluster randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID‐19 (ARCHAIC) – Protocol publication
has PubMed Central identifier	PMC7300462
has PubMed identifier	32474918
schema:publication	Eur J Clin Invest
resource representing a document's body	covid:71403b97afb2fced959e2d5a1b146ede82872dcd#body_text
is schema:about of	named entity 'rheumatologic' named entity 'Authors' named entity 'chloroquine' named entity 'author' named entity 'tolerability' named entity 'randomized controlled trial' named entity 'COVID-19' named entity 'reduce' named entity 'China' named entity 'antiviral' named entity 'HCQ' named entity 'hydroxychloroquine' named entity 'Drs.' named entity 'COVID' named entity 'metabolism' named entity 'renal impairment' named entity 'supportive care' named entity 'chloroquine' named entity 'chloroquine' named entity 'COVID' named entity 'hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'intra-cluster correlation' named entity 'COVID-19' named entity 'COVID' named entity 'research groups' named entity 'copyright' named entity 'Supportive care' named entity 'chloroquine' named entity 'HCQ' named entity 'COVID-19' named entity 'sample size' named entity 'adverse events' named entity 'antiviral therapy' named entity 'estimated glomerular filtration rate' named entity 'nasogastric tube' named entity 'lungs' named entity 'myocardial infarction' named entity 'informed consent' named entity 'copyright' named entity 'research team' named entity 'primary endpoint' named entity 'mode of action' named entity 'Hydroxychloroquine' named entity 'maintenance dose' named entity 'clinical trials' named entity 'COVID' named entity 'safety profile' named entity 'Supportive care' named entity 'hydroxychloroquine' named entity 'intra-cluster correlation' named entity 'cellular replication' named entity 'immune response' named entity 'tablets' named entity 'HCQ' named entity 'follow-up' named entity 'research team' named entity 'Covid-19' named entity 'sample size' named entity 'absolute risk reduction' named entity 'nasopharyngeal' named entity 'renal impairment' named entity 'congenital' named entity 'hydroxychloroquine' named entity 'COVID' named entity 'copyright' named entity 'tube feeding' named entity 'hydroxychloroquine' named entity 'chronic lung disease' named entity 'COVID' named entity 'QT interval prolongation' named entity 'hydroxychloroquine' named entity 'chloroquine' named entity 'design effect' named entity 'COVID-19' named entity 'loading dose' named entity 'primary endpoint' named entity 'primary endpoint' named entity 'chloroquine' named entity 'primary endpoint' named entity 'cardiovascular disease' named entity 'statistically significant'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software